Genzyme Corp. (GENZ) is down close to 5% on higher than-usual volume of 3.5 million shares, compared with the average of 2.1 million.
The company missed estimates by 2 cents, or 2.13%, in its first quarter with earnings of 92 cents per share.
The 2009 average forecast for this Zacks #4 Rank (“Sell”) company declined a penny to $3.04 per share over the past 30 days.
“GENZ” Free Stock Analysis: Buy? Sell? Hold?
Zacks Investment Research
